Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M‐positive NSCLC: A retrospective study.

Autor: Zhou, Bin1, Gong, Qiang1, Li, Ben1, Qie, Hai‐Ling1, Li, Wei1, Jiang, Hong‐Tao1 aq126@163.com, Li, He‐Fei1 13831275950@163.com
Zdroj: Journal of Clinical Pharmacy & Therapeutics. May2022, Vol. 47 Issue 5, p643-651. 9p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje